| |
|
|
|
|
|
|
|||
|
Blood, 1 August 2006, Vol. 108, No. 3, pp. 821-829. Prepublished online as a Blood First Edition Paper on April 11, 2006; DOI 10.1182/blood-2005-11-006817.
CHEMOKINES, CYTOKINES, AND INTERLEUKINS RAX, the PKR activator, sensitizes cells to inflammatory cytokines, serum withdrawal, chemotherapy, and viral infectionFrom the Shands Cancer Center and Department of Immunology and Molecular Genetics, University of Florida, Gainesville, Florida; and Department of Innovative Therapy, Advanced Biotechnology Center, Genoa, Italy.
While the interferon (IFN)inducible double-stranded RNA (dsRNA)dependent protein kinase PKR is reported to initiate apoptosis in some instances, the mechanism by which diverse stress stimuli activate PKR remains unknown. Now we report that RAX, the only known cellular activator for PKR, initiates PKR activation in response to a broad range of stresses including serum deprivation, cytotoxic cytokine or chemotherapy treatment, or viral infection. Thus, knock-down of RAX expression by 80% using small interfering RNA (siRNA) prevents IFN /tumor necrosis factor (TNF )induced PKR activation and eIF2 phosphorylation, I B degradation, IRF-1 expression, and STAT1 phosphorylation, resulting in enhanced murine embryonic fibroblast (MEF) cell survival. In contrast, expression of exogenous RAX, but not of the nonphosphorylatable, dominant-negative RAX(S18A) mutant, sensitizes cells to IFN /TNF , mitomycin C (MMC), or serum deprivation in association with increased PKR activity and apoptosis. Furthermore, RAX(S18A) expression in Fanconi anemia complementation group Cnull MEF cells not only prevents PKR activation but also blocks hypersensitivity to IFN /TNF or mitomycin C that results in enhanced apoptosis. In addition, reduced RAX expression facilitates productive viral infection with vesicular stomatitis virus (VSV) and promotes anchorage-independent colony growth of MEF cells. Collectively, these data indicate that RAX may function as a negative regulator of growth that is required to activate PKR in response to a broad range of apoptosis-inducing stress.
Previously, we discovered that interleukin-3 (IL-3) withdrawal from factor-dependent myeloid cells activated the interferon-inducible double-stranded RNA (dsRNA)dependent protein kinase, PKR, in a mechanism that leads to translation inhibition and induction of apoptosis.1 This finding and latter observations by others that platelet-derived growth factor (PDGF) and tumor necrosis factor (TNF ) signaling require PKR, underscore the notion that PKR is not only involved in host antiviral defense, but also in cellular growth signaling.2,3 Furthermore, reports indicate that PKR functions in the cellular response to inflammatory cytokines interferon (IFN ) and TNF , and in Toll-like receptor signaling pathways, indicating that PKR may play a broader role in mediating both cellular stress and the innate immune responses.4-13 It has been proposed that PKR serves as a "molecular clock" during stress that sequentially promotes cell survival then induces apoptosis.14 In this regard, PKR is thought to initiate nuclear factor B (NF- B)mediated gene expression and survival by a kinase-independent mechanism but, following prolonged stress, can become catalytically activated to inhibit translation and induce apoptosis. Thus, determining the molecular mechanism(s) by which this Jekyll-and-Hydelike transformation of PKR may occur during the course of cellular stress is paramount to our understanding of how stress-activated signal transduction pathways are regulated. Recently, we identified RAX, the only known cellular activator of PKR, and reported that RAX phosphorylation on serine 18 is required for PKR activation, translation inhibition, and apoptosis following IL-3 deprivation.15,16 RAX and its independently discovered human ortholog PACT are ubiquitously expressed, 98% identical, and consist of 3 dsRNA-binding domains.15,17,18 The N-terminal first and second dsRNA-binding domains are necessary for association with dsRNA and PKR while the third, C-terminal domain is not required for dsRNA or PKR binding but is required for PKR kinase activation.19,20 Interestingly, expression of the nonphosphorylatable RAX(S18A) mutant promotes a dominant-negative phenotype when IL-3 is withdrawn from factor-dependent cells characterized by failure to activate PKR, delayed translation inhibition, and enhanced cell survival.16 However, it remains uncertain whether only specific cellular stresses such as growth factor deprivation, or rather various stresses, including cytotoxic drug or cytokine treatment and viral infection, coordinate apoptosis signaling through a RAX-dependent mechanism.
PKR is required for the cytotoxic response to the inflammatory cytokine TNF
Since PKR plays a critical role in regulating cell growth and apoptosis, it is not surprising that PKR has been associated with the molecular phenotype of several diseases, including Fanconi anemia (FA).26 Cells from FA patients are hypersensitive to DNA crosslinking agents such as mitomycin C and exhibit increased apoptosis induced by inflammatory cytokines. These phenotypes may ultimately lead to bone marrow failure and leukemia in FA patients.27 Interestingly, forced expression of the dominant-negative PKR mutant PKR (K296R) in primary FA lymphoblasts potently suppresses apoptosis induced by IFN
To examine the role of RAX during the cellular response to various cytotoxic stress applications, we generated MEF cell lines that express either markedly reduced (ie, > 80%) levels of RAX, exogenous RAX, or the nonphosphorylatable RAX(S18A) mutant. Results indicate that RAX functions as the necessary direct upstream regulator of PKR in a stress
Cell lines and reagents Simian virus 40 (SV40) large T-antigenimmortalized normal and Fancc/ MEFs derived from C57BL and 129Sv were from G. C. Bagby (Oregon Health & Science University [OHSU] Cancer Institute, Portland, OR). The retroviral vector pBMN-Z-I-blasto and Phoenix retrovirus producer cell line were from G. P. Nolan (Stanford University, CA). Cells were maintained in Dulbecco modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and cultured in a humidified incubator at 37°C and 5% CO2 (Invitrogen, Carlsbad, CA). BHK-21 cells were maintained in F11 medium supplemented with 1% nonessential amino acids, 1% penicillin-streptomycin solution, 2% 200 mM glutamine, 0.7% glucose, and 10% FBS (Invitrogen). To generate retroviral RAX and RAX(S18A) expression vectors, N-terminal FLAG-tagged RAX or RAX(S18A) were cloned into pBMN-Z-I-blasto as BamHI fragments, thereby replacing the LacZ gene. The resulting vectors, called pBBFlagRAX and pBBFlagRAX(S18A), express either FLAG-tagged RAX or RAX(S18A) from the Moloney murine leukemia virus (MoMLV) 5' long terminal repeat (LTR), respectively. Phoenix packaging cells were transfected using Lipofectamine (Invitrogen, Carlsbad, CA). Approximately 24 hours after transfection, 3 mL of medium from the Phoenix cells was used to infect 2 x 105 MEF cells. After infection (24 hours), the medium was replaced, and 48 hours after infection, cells were selected with 4 µg/mL blasticidin S (no. 203 350; Calbiochem, La Jolla, CA). Immunoblotting using antibody to RAX or FLAG (no. F1804; Sigma-Aldrich, St Louis, MO) confirmed expression.
Antibodies to I Generation of cell lines expressing RAX siRNA The pSUPER RNAi system (Oligoengine, Seattle, WA) was used to produce vectors expressing RAX siRNAs. The Oligoengine design tool (www.oligoengine.com) and the Dharmacon siDESIGN tool (www.dharmacon.com/sidesign/; Dharmacon, Lafayette, CO) were used to devise 13 siRNA oligonucleotides to RAX. A negative control siRNA (nc siRNA) was designed by scrambling the sequence of si100. A basic local alignment search tool (BLAST) search (http://www.ncbi.nlm.nih.gov/) confirmed that each siRNA had no significant homology to any gene other than RAX. The 5' to 3' target sequences were: si100, CACCGATTCAGGTATTGCA; si164, AAGATCCGATGTGCAAGTA; si165, AGATCCGATGTGCAAGTAC; si166, GATCCGATGTGCAAGTACA; si210, ACCGTTGGTGACATAACTT; si211, CCGTTGGTGACATAACTTG; si310, GTATTTGCTTTGCAGTTCC; si340, TGCCTGATCCATCCAAACA; si467, AGAGGGAATACACCACGAT; si581, TATTTCTCCAGAGAACCAC; si610, CGAACGTGGTTGGACATTC; si937, AGTAGGCTTGGAGCGACTT; si938, GTAGGCTTGGAGCGACTTA; and nc siRNA, GACGAAAGCAGTTCGTCTA. For each target sequence, 64-base complementary oligonucleotides were purchased (Sigma-Genosys, St Louis, MO), hybridized, and ligated into pSUPER.retro.puro according to Oligoengine's protocol. DNA sequence analysis confirmed constructs (University of Florida, Gainesville, FL). Phoenix cells were transfected with siRNA plasmids. After 48 to 72 hours, the resulting media was used to infect MEF cells as described, and cells were selected in 5 µg/mL puromycin. Cells were lysed in GLB (20 mM Tris-Cl [pH 7.6], 137 mM NaCl, 5 mM EDTA, 1% triton X-100, 15% glycerol, and 1 x protease inhibitor cocktail I [no. 539131; Calbiochem])16 and expression of PKR and RAX was determined by immunoblotting using antibody to PKR (1:1000, sc-1702, M-515, SCB) or RAX (1:500 dilution)15 and secondary horseradish peroxidase (HRP)conjugated antibody (SCB) with enhanced chemiluminescence (ECL) reagents (GE Healthcare, Piscataway, NJ). Western blots were scanned at 400 dots per inch (dpi) and saved as TIFF files. Individual bands were quantified by densitometry analysis with background correction using Quantity One (Bio-Rad Laboratories, Hercules, CA). Viability and apoptosis measurement
Viability during normal growth was determined by trypan blue dye exclusion. To measure viability and apoptosis under stress conditions, cells were plated at 5 x 105 cells/well in a 6-well plate. Where indicated, cells were treated for 24 hours with 10 or 20 ng/mL IFN
PKR and eIF2 PKR autophosphorylation activity at the indicated times was assayed by 32P incorporation after immunoprecipitation.16 Briefly, PKR antibodies M-515 and B-10 (SCB) were used to immunoprecipitate and detect total PKR, respectively, from 250 µg cell lysate, and kinase reactions using immunoprecipitated PKR were performed for 15 minutes at 30°C with 32P-labeled ATP as previously described.16 Autoradiographs and immunoblots were scanned, saved as TIFF files, and quantified as described. The average change in phosphorylation level relative to any change in total protein level at each time point following stress treatment was calculated and compared with untreated cells. For all figures, the mean of 3 separate experiments was graphed with error bars depicting the standard deviation.
The level of eIF2
Statistical significance (P < .1) of the differences observed between cell lines or time points for viability, PKR activity, and eIF2 Vesicular stomatitis virus infection, titering, and immunoblotting MEF cell lines were infected with vesicular stomatitis virus (Indiana serotype) at a multiplicity of infection (MOI) of 1 or 5 for 1 hour at 37°C. Viability was measured 0, 8, and 24 hours after infection using trypan blue dye exclusion. After 24 hours of infection, culture medium was removed and saved while the infected cells were lysed, as described, to monitor viral protein levels by immunoblotting with antibody R1. Virus titer of the medium was determined on monolayers of BHK-21 cells at 37°C. Anchorage-independent growth assay Colony formation in soft agar medium after 14 days was quantified to measure cell transformation of MEF cells stably expressing RAX constructs. Briefly, 1 x 104 cells were mixed with complete medium containing 0.4% agarose and plated in a 60-mM dish over a base layer of solidified 0.8% agarose in complete medium. Plates were incubated at 37°C and medium replenished every 3 to 4 days. Crystal violetstained plates were scanned at 300 dpi using a flatbed scanner (Pixma MP 780; Canon, Lake Success, NY) and enlarged printouts were used to count colonies (groups of approximately 50 or more cells).
Cells expressing reduced RAX display increased survival under low-serum conditions
MEF cell lines with reduced RAX expression were created using siRNAs. Thirteen siRNAs were tested that extensively cover the RAX sequence. Following retroviral packaging, siRNA vectors were delivered to MEF cells, and cells were selected for stable expression. Three siRNA-expressing cell lines, si164, si165, and si166, displayed 81%, 54%, and 32% reduced RAX expression, respectively, compared with a scrambled nc siRNA (Figure 1A). In addition, MEFs stably expressing either an N-terminal FLAG-tagged RAX or the dominant-negative nonphosphorylatable RAX(S18A) mutant were also generated. Importantly, RAX or RAX siRNA expression did not alter the expression of PKR, TNF
RAX expression is required for IFN
To investigate the role of RAX during apoptosis initiated by cell stress other than IL-3 deprivation,16 we measured the effect of IFN
Since RAX is the only identified cellular activator of PKR to date, we examined PKR activation by measuring the change in PKR autophosphorylation activity relative to the total PKR protein level after IFN
Since eIF2 is a primary substrate for PKR, we measured eIf2 phosphorylation at serine 51 to confirm PKR activation.11 After 24 hours with IFN , control siRNA and vector-onlyexpressing cells exhibited an approximately 2.7-fold increase in eIF2 phosphorylation relative to total protein level (P = .007, n = 3), and subsequent cotreatment of these cells with TNF for up to 24 hours did not further increase eIF2 phosphorylation compared with un-treated cells (Figure 2E). Significantly, RAX overexpressing cells displayed an initial 3-fold increase in relative eIF2 phosphorylation following IFN treatment (P = .02, n = 3), which rapidly escalated following TNF cotreatment to an approximately 7-fold increase compared with untreated cells (P = .03, n = 3; Figure 2E). In contrast, cells expressing the nonphosphorylatable RAX(S18A) mutant displayed markedly reduced eIF2 phosphorylation after either IFN or IFN /TNF cotreatment compared with vector-only control cells (ie, approximately 1.9-fold vs approximately 2.7-fold after 24 hours of IFN , P = .07, n = 3; Figure 2E). Importantly, the si164-expressing cells displayed no significant increase in eIF2 phosphorylation after either IFN or IFN /TNF treatment (Figure 2E). Thus, failure of IFN /TNF cotreatment to promote apoptosis is likely caused, at least in part, by the failure of RAX to properly activate PKR.
Reduced RAX expression is associated with aberrant transcription factor activation by IFN
Several reports indicate that PKR-mediated signal transduction enhances TNF
STAT1 expression and activation as monitored by phosphorylation at serine 727 were also determined after IFN
Expression of the nonphosphorylatable RAX(S18A) mutant suppresses Fancc-null cells' hypersensitivity to IFN
The Fanconi anemia complementation group C (Fancc) gene product may protect cells from PKR-mediated cytotoxicity by cooperating with Hsp70 to inhibit PKR activity.29 MEFs derived from Fancc/ mice have constitutively activated PKR, which may contribute to their hypersensitivity to IFN
We tested Fancc/ MEFs that stably express similar levels of either FLAG-tagged RAX or the nonphosphorylatable RAX(S18A) mutant (Figure 4A). Importantly, overexpression of RAX or RAX(S18A) did not alter TNF-R1, IFN -R , or PKR expression, indicating that differences observed in these cells are likely specific to RAX (Figure 4A). The Fancc/ cells with increased RAX expression were more sensitive than vector-only control cells to treatment with either IFN (approximately 75% vs approximately 85% viable, P = .04, n = 4) or TNF alone (approximately 60% vs approximately 88%, P < .001, n = 4), and also exhibited enhanced cell death following IFN /TNF cotreatment (approximately 34% vs approximately 60%, P < .001, n = 4; Figure 4B). Significantly, expression of the nonphosphorylatable RAX(S18A) mutant, at least in part, suppressed IFN /TNF apoptosis compared with vector-only control cells (approximately 69% vs approximately 60% viable, P = .08, n = 4; Figure 4B).
Next, we examined PKR activation in Fancc/ cells expressing exogenous RAX or RAX(S18A) following IFN Since a molecular hallmark of FA cells is sensitivity to DNA damage induced by crosslinking agents such as mitomycin C (MMC), we tested whether RAX expression in Fancc/ MEF cells altered these cells' hypersensitivity to MMC. Similar to findings by others, Fancc/ vector-only control cells were much less viable than normal MEF vector-only control cells after treatment with increasing concentrations of MMC for 24 hours (Figure 4D). At the highest dose tested (400 ng/mL), Fancc/ vector-only control cells were approximately 44% viable compared with normal MEFs that were approximately 72% viable (P = .03, n = 4; Figure 4D). MMC did not alter endogenous RAX or PKR expression (data not shown). However, exogenous RAX expression greatly sensitized (approximately 26% vs approximately 44% viable, P = 0.01, n = 4), while expression of the nonphosphorylatable RAX(S18A) mutant protected Fancc/ cells (approximately 56% vs approximately 44% viable, P = .05, n = 4) from MMC compared with vector-only control cells (Figure 4D). These findings may indicate that the RAX-PKR signaling pathway contributes to hypersensitivity to inflammatory cytokines and DNA damage observed in Fancc/ cells.
RAX is required for host antiviral defense to VSV infection PKR may be activated by dsRNA produced during viral infection including with VSV.35 To investigate whether the PKR activator RAX is also necessary for host antiviral defense or whether PKR functions independently following infection, MEFs with reduced RAX were tested for sensitivity to VSV. After 24 hours of infection with an MOI of 1 or 5, si164-expressing cells were only approximately 15% or approximately 10% viable, respectively, compared with control siRNA cells that remained approximately 78% viable (P = .03 and .01, respectively, n = 3; Figure 5A). Furthermore, exogenous expression of RAX, but not the nonphosphorylatable RAX(S18A) mutant, increased cell death following viral infection such that only approximately 41% compared with approximately 88% for vector-only control cells were viable (MOI 1, P = .002, n = 3; Figure 5A). The si164-expressing cells failed to activate PKR compared with an approximately 2.5-fold activation in control siRNA cells following 4 hours of VSV infection (MOI 1, P = .001, n = 3; Figure 5B). In addition, PKR activity was reduced 50% by 24 hours of infection in the si164-expressing cells (P = .02, n = 3; Figure 5B). Significantly, in cells expressing exogenous RAX, relative PKR activity was approximately 2.7-fold higher than uninfected cells by 4 hours of infection, which was maintained throughout the infection (P = .01, n = 3; Figure 5B). Furthermore, after 24 hours of infection, the relative PKR activity in RAX-expressing cells was twice that of vector-only control cells (ie, approximately 3-fold vs approximately 1.5-fold, P = .001, n = 3; Figure 5B). In contrast, cells expressing the nonphosphorylatable RAX(S18A) mutant displayed a significant inhibition of PKR activity after 4 hours compared with vector-only control cells (ie, approximately 1.8-fold vs approximately 2.6-fold, respectively, P = .03, n = 3; Figure 5B). Thus, unlike the si164-expressing cells, where RAX is reduced by more than 80% and PKR fails to be activated, PKR is still activated to some extent in the RAX(S18A)-expressing cells but not to the same level as observed in vector-only control cells.
MEF si164-expressing cells with reduced RAX also fail to phosphorylate and inactivate eIF2
Most likely as a direct consequence of the inability to activate PKR, phosphorylate eIF2 Knock-down of RAX expression or forced expression of RAX(S18A) promotes anchorage-independent colony formation in soft agar Since RAX can activate PKR, and PKR has been associated with inhibition of cell growth and viability, we assessed the oncogenic potential of RAX by assaying anchorage-independent growth capacity in soft agar of MEF cells with reduced RAX expression, exogenous RAX, or the nonphosphorylatable RAX(S18A) mutant. Interestingly, while vector-only control MEF cells form colonies (defined as groups of 50 or more cells) in soft agar with an efficiency of approximately 4.4%, cells expressing exogenous RAX display about a 7-fold reduction in transformation efficiency (0.6% vs 4.4%, respectively, P = .001, n = 4; Figure 6). In contrast, expression of the nonphosphorylatable RAX(S18A) mutant more than tripled the anchorage-independent growth capability of these cells compared with vector-only MEF cells (14.9% vs 4.4%, P = .001, n = 4, respectively; Figure 6). In addition, si164 cells, with reduced RAX, displayed about twice the level of colony formation in soft agar as that of control cells (7.4% vs 4.4%, P = .004, n = 4; Figure 6). Taken together, these results suggest that RAX may contribute to growth inhibition.
Our results demonstrate that RAX is required to effectively activate PKR and initiate apoptosis during a variety of cytotoxic cell-stress applications, including serum depletion, cytotoxic drug or cytokine treatment, and viral infection. Cells with reduced RAX expression display a significant defect in the stress response as evidenced by failure to fully activate PKR and phosphorylate eIF2 , degrade I B, induce IRF-1, and phosphorylate STAT1 following IFN /TNF treatment. In contrast, increased RAX expression in MEFs promoted the opposite phenotype of more rapid PKR activation, which increased eIF2 phosphorylation, I B degradation, IRF1 expression, and STAT1 phosphorylation during IFN /TNF treatment, leading to more rapid apoptosis. Thus, understanding the mechanism by which RAX regulates the molecular components of stress signaling and gene expression will be an important area of future research. Our results also suggest that RAX is required for the host antiviral response to VSV infection, since viral protein production and titer are drastically reduced in cells expressing exogenous RAX, while alternatively, an increase in viral productivity occurs in RAX "knock-down" cells. Increased RAX expression promotes enhanced PKR activity and apoptosis following VSV infection, while cells with reduced RAX expression fail to activate PKR and display increased cell death due to rampant viral production. Although the exact mechanism by which RAX regulates the response to VSV infection remains to be determined, RAX is clearly required for PKR activation. Furthermore, since RAX, like PKR, is a dsRNA-binding protein, it seems likely that some dsRNA species produced during infection may promote RAX activation of PKR. Alternatively, it is possible that some other cellular signal activated during VSV infection initiates the RAX-dependent antiviral mechanism.
Interestingly, and consistent with findings using cells that express either a dominant-negative PKR mutant, a nonphosphorylatable eIF2
Previously, we reported that expression of the nonphosphorylatable RAX(S18A) mutant led to prolonged survival (a dominant-negative phenotype) following IL-3 withdrawal from factor-dependent myeloid cells.16 Results here extend those findings to include a role for RAX phosphorylation in the cellular response to diverse stress applications and suggest that these stresses may promote RAX phosphorylation and activation. Significantly, forced expression of the nonphosphorylatable RAX(S18A) mutant in normal and Fancc/ MEFs was found to significantly block cell hypersensitivity to IFN /TNF or MMC. These findings support the notion that defects in extracellular signaling pathways and the RAX-PKR stress-response signaling axis may contribute to the DNA repair defect and inflammatory cytokine hypersensitivity phenotype reported for FA cells.29,30 These findings also suggest that blocking RAX-dependent PKR activation in FA-C patient cells may have potential therapeutic value by enhancing survival during stress. However, this possibility will now need to be tested in primary cells from FA-C patients.
In summary, results indicate that cells with decreased RAX expression not only fail to activate PKR but also display prolonged survival in response to various cytotoxic stresses, including serum starvation, treatment with cytotoxic cytokines or chemotherapy, or viral infection. We therefore propose that under various diverse stress situations RAX functions as the upstream activator of PKR in a stress
We would like to thank S. Smallwood for providing technical assistance with the VSV work.
Submitted November 30, 2005; accepted March 11, 2006.
Prepublished online as Blood First Edition Paper, April 11, 2006; DOI 10.1182/blood-2005-11-006817.
Supported by National Institutes of Health grant 5R01HL054083-8. W.L.B. was funded by National Research Service Award (NRSA) CA09126-27.
R.L.B. and W.L.B. contributed equally to this work.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: W. Stratford May, 1600 SW Archer Rd, Room N5-503, Box 100232, Gainesville, FL 32610-0232; e-mail: smay{at}ufscc.ufl.edu.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2006 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||